Riyadh headquarters
On-hand inventory managed on a FEFO basis with minimum shelf-life controls and reorder triggers — so the import lead time sits with us, not with your clinical schedule.
About Afiyatech
Afiyatech Commercial Company supplies diagnostics, specimen collection, immunoassay reagents, clinical chemistry, infection control and laboratory equipment to hospitals, reference laboratories and medical centres across Saudi Arabia. We hold stock in Riyadh, source through SFDA-registered routes, and take ownership of what happens to a product after it reaches your shelf.
How we are set up
Buying six categories from one supplier only helps if that supplier can actually carry them. These are the capabilities that let us do it.

The people who use itProduct selection is agreed with the laboratory that will run it.
Riyadh warehouseFEFO rotation, minimum shelf-life controls and reorder triggers.
Cold chain2–8 °C and −20 °C storage, monitored and logged.
Lot traceabilityLot-level tracking from purchase order to clinical use.
On-hand inventory managed on a FEFO basis with minimum shelf-life controls and reorder triggers — so the import lead time sits with us, not with your clinical schedule.
One named point of contact who knows your platforms, your usage and your validation history. Technical support for product selection and compatibility, not a call centre.
Reach beyond the capital into clinics and laboratories across the Kingdom, without the account relationship changing hands.
From national hospital groups and reference laboratories to polyclinics and independent specialist centres — the same catalogue and the same terms.
What we commit to
These are not service aspirations. They are the terms on which we ask laboratories to consolidate their supply with us.
We will never substitute a product without explicit buyer approval. No catalogue-number switching, no ‘equivalent product’ replacement without IFU validation and your sign-off.
All products sourced via MDMA-approved routes with Authorised Representative coverage, and full documentation available at time of purchase — no compliance surprises at audit.
Lot-level tracking from purchase order to clinical use, supporting post-market surveillance, recall management and CBAHI/JCI audit requirements.
We track lot numbers, manage complaints and recalls, and report field safety corrective actions on your behalf.
How this is enforced: every new product runs through five structured gates before it reaches a department — product match, regulatory check, pilot validation, inventory control and post-market discipline. See the process.
Who we represent
Afiyatech distributes established international manufacturers rather than unbranded equivalents. Where a category has more than one credible maker, we stock more than one — so your procurement team has a choice of format, pack size and price point without changing supplier.
Company standing and distribution authority, available on request and at audit.
Commercial registration
CR 101088142
VAT certificate
313050062700003
Copan authorisation
Authorised distributor, KSA
SFDA documentation
Per-SKU, at purchase
Registration status is product-specific and confirmed per SKU at time of quotation. All brand names are the property of their respective manufacturers.
Brands named are manufacturers distributed by Afiyatech. SFDA registration status must be confirmed per product at time of purchase. All brand names are the property of their respective manufacturers.
Where we sit in the market
Vision 2030 transformation, mandatory SFDA registration and NUPCO centralised procurement have raised the bar on compliance since 2022. Afiyatech was built for that frame rather than retrofitted to it.
Every medical device and IVD must hold current MDMA approval via a Saudi-licensed Authorised Representative. Purchasing from an unregistered source exposes your facility to regulatory risk and product liability.
The Kingdom’s SAR 25bn+ unified procurement channel covers 500+ public facilities. Participation requires verified SFDA status and a compliant local supply chain from day one.
Rapid expansion in hospitals, reference labs and polyclinics is driving demand for CBAHI, JCI and CAP accreditation — all of which scrutinise supply-chain compliance, lot traceability and product documentation.
Sources: SFDA MDMA/GHAD guidance (2026); NUPCO public data; Saudi Vision 2030 health programme. See Evidence for the full list.
Start with a fact base
We audit your current supplier list, product usage, rejection rates and stock policy — then pilot a handful of SKUs before anything is standardised. No commitment required at the first step. See the 30 / 60 / 90-day plan.